Ohr Pharmaceutical Inc.

Magainin Pharmaceuticals, Inc.

Endo Ventures Limited

Genaera Corporation

Endo Operations Limited

Depymed, Inc.

Michael McLane

Henry Raphael Wolfe

Inez Ruiz-White

Mark L Anderson

William Alvin Kinney

Michael A Zasloff

W Lee Maloy

Jon I Williams

Genzhou Liu

Jeffrey Davidson

Taffy J Williams

U Prasad Kari

Ann Shinnar

Henry R Wolfe

Xuehai Zhang

Roy C Levitt, Jr

Mary Doubleday

Charles W Gilbert

Kyle Armbruster

Eric Chellquist

The present disclosure relates to a method for rating the severity of cellulite on a thigh or buttock in a human subject by utilizing a photonumeric scale that provides reliable results from physician-to-physician and patient-to-patient.

Method of assessing and treating cellulite

This application is directed to the use of aminosteroid compounds for the selective inhibition of the enzyme PTP1B in a mammal for the treatment of diabetes.

Aminosteroids for the treatment of a PTP1B associated disease

This application is directed to the use of steroid compounds for the selective inhibition of the enzyme PTP1B in a mammal for the treatment of diabetes.

Method for treating diabetes

A pharmaceutical composition includes, as an active ingredient, a compound according to formula 1436 as shown in FIG., or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient. Various pharmaceutical products may be produced including this pharmaceutical composition. Such pharmaceutical products may be used for the treatment of obesity or diabetes. Methods for using the pharmaceutical compositions also are described. In these methods, various diseases are treated or other body functions are activated or inhibited by administering an effective amount of the pharmaceutical composition. For example, diabetes and obesity may be treated by administering an effective amount of the pharmaceutical compositions. Weight gain and growth factor production can be inhibited by administering an effective amount of these pharmaceutical compositions. Appetite can be suppressed by administering an effective amount of the pharmaceutical compositions, and a diuretic effect can be produced.

Therapeutic uses for an aminosterol compound

The invention relates to select squalamine salts, methods of their synthesis, their therapeutic use and their advantages relating to manufacturing, product stability and toxicity. More specifically, this application is directed to various forms of the dilactate salt of squalamine and their utility in inhibiting neovascularization and endothelial cell proliferation.

Polymorphic and amorphous salt forms of squalamine dilactate

A pharmaceutical composition includes, as an active ingredient, a compound according to formula 1436 as shown in FIG., or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient. Various pharmaceutical products may be produced including this pharmaceutical composition. Such pharmaceutical products may be used for the treatment of obesity or diabetes. Methods for using the pharmaceutical compositions also are described. In these methods, various diseases are treated or other body functions are activated or inhibited by administering an effective amount of the pharmaceutical composition. For example, diabetes and obesity may be treated by administering an effective amount of the pharmaceutical compositions. Weight gain, and growth factor production can be inhibited by administering an effective amount of these pharmaceutical compositions. Appetite can be suppressed by administering an effective amount of the pharmaceutical compositions, and a diuretic effect can be produced.

Therapeutic uses for aminosterol compounds

Biologically active peptides with reduced toxicity in animals and a method for preparing same

Aminosterol compounds are described that are useful as inhibitors of the sodium/proton exchanger (NHE). Methods of using such aminosterols compounds are also disclosed, including those employing compounds that are inhibitors of a spectrum of NHEs as well as those using compounds that are inhibitors of only one specific NHE. Advantageous screening techniques and assays for evaluating a compound's therapeutic activity are also disclosed.

Method of inhibiting profileration of cells by administering an

Growing community of inventors

Lansdale, PA, United States of America

Michael McLane